Will 2013 see more medtech migration into pharma arena?
This article was originally published in Clinica
Looking ahead at what's in store for 2013, one of the overarching trends that Clinica predicts is the increased presence of medtech players in areas that have until now been traditionally dominated by pharma. This itself could lead to more cross-sector investment/partnerships with pharma firms potentially looking to maintain their stronghold in a disease area and buy medtech alternatives to their drug offering, or medtech firms partnering with pharma to develop the devices required for more effective delivery of drugs.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.